Tevogen Bio Holdings Inc. (TVGN)
$6.51-8.44%Close
SELLRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $27M
- Beta
- 0.20
- P/E (TTM)
- -1.12
- Short % float
- 5.18%
- Days to cover
- 10.6
- SI change
- -4.7%
- 1W
- +0.31%
- 1M
- -16.00%
- vs SPY 1W
- +1.29%
- vs SPY 1M
- -17.86%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 12
- GROWTH
- 35
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC149.1%
REV YoY-
ROE248.5%
EPS YoY-
ROA-457.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.12
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-2.80
P/FCF-
EV/EBITDA-1.39
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.33
ND/EBITDA-
BETA0.20
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
LOW CONFIDENCE · 13/20
PROFIT FACTOR0.6
TRADES13
[REGIME]FULL HISTORY
RECOVERY
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on TVGN?
- LOPJLB’s latest quantitative signal on Tevogen Bio Holdings Inc. (TVGN) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is TVGN in?
- Tevogen Bio Holdings Inc. (TVGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Tevogen Bio Holdings Inc. (TVGN) do?
- Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing lon…